Vital-Imi
  • HOME
  • ABOUT
    • PARTNERS
    • WORK PACKAGES
      • Work Package 1
      • Work Package 2
      • Work Package 3
      • Work Package 4
      • Work Package 5
  • PUBLICATIONS
  • UPDATES
  • MENU
    • EVENTS
    • PARTNERS
    • NEWSLETTER
    • CONTACT
    • PRIVACY POLICY
    • LOGIN
  • Search
  • Menu Menu

PUBLICATIONS

All 15 /Publications 15

Identification of aging-associated immunotypes and immune stability as indicators of post-vaccination immune activation

Using qualitative research to develop an elaboration of the TIDieR checklist for interventions to enhance vaccination communication: short report

Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population

Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond

Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom

Healthcare Workers’ Perceptions and Experiences of Communicating with People over 50 about Vaccination

European data sources for computing burden of (potential) vaccine-preventable diseases in ageing adults

Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program

Health Economics of Vaccines: From Current Practice to Future Perspectives

Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands

Consultations for Influenza-Like Illness in Primary Care in The Netherlands: A Regression Approach

Preventing Infectious Diseases for Healthy Ageing: The VITAL Public-Private Partnership Project

Characteristics of Effective Educational Interventions Targeting Healthcare Workers to Improve Advising about Vaccinations for Adults of 50 Years and Older

Short- and Long-term Impact of Vaccination against Cytomegalovirus: a Modeling Study

Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives

Page 1 of 212

Newsletter

Contact

You can contact us by using the contact form here.

Follow us

  • twitter

The VITAL project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806776. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Scroll to top